Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)

Source-based overview

The purpose of this notice of funding opportunity (NOFO) is to identify modifiable mechanisms and therapeutic targets to address central nervous system (CNS) complications associated with human immunodeficiency virus (HIV). The initiative supports a phased research approach beginning with the identification of patient phenotypes characterized by convergent pathophysiological features, followed by the discovery and experimental validation of molecular mechanisms using innovative in-vitro and in-vivo models. The goal of this NOFO is to advance therapeutic target, and intervention discovery to address the multifactorial and heterogeneous nature of HIV-associated CNS dysfunction. The official record contains the controlling eligibility, budget, attachment and submission requirements for opportunity RFA-MH-27-125.

Eligibility

Eligible applicant types listed by the agency: Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments); Special district governments; Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; For profit organizations other than small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal governments (Federally recognized); Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; State governments; Private institutions of higher education; City or township governments. Applicants must also satisfy every programme-specific condition in the official notice.

Funding and benefits

Award ceiling: See official notice

Themes and supported activities

The purpose of this notice of funding opportunity (NOFO) is to identify modifiable mechanisms and therapeutic targets to address central nervous system (CNS) complications associated with human immunodeficiency virus (HIV). The initiative supports a phased research approach beginning with the identification of patient phenotypes characterized by convergent pathophysiological features, followed by the discovery and experimental validation of molecular mechanisms using innovative in-vitro and in-vivo models. The goal of this NOFO is to advance therapeutic target, and intervention discovery to address the multifactorial and heterogeneous nature of HIV-associated CNS dysfunction.

Opportunity number: RFA-MH-27-125

Deadline and timeline

Applications close 2027-10-28: Applications close 2027-10-28: Oct 28, 2027.

Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.

How to apply

Open the official Grants.gov record, review the full notice and attachments, and use the application package or agency route stated there.

Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.